How long is treatment and follow-up?

Treatment usually includes evaluation, stem cell collection, manufacturing time, conditioning, infusion, recovery, and long-term follow-up at a specialized center.

Beta-Thalassemia Gene Therapy Guide

Q: Is gene therapy available for beta-thalassemia?

Yes. FDA-approved gene therapy options are available for selected patients with transfusion-dependent beta-thalassemia.

Q: Does it help patients who need regular transfusions?

Gene therapy is designed to reduce or potentially eliminate the need for regular red blood cell transfusions in appropriate patients.

Q: What is the difference between Casgevy and Zynteglo?

Casgevy is a gene-edited autologous stem cell therapy, while Zynteglo is a gene-addition autologous stem cell therapy.

Q: What are the main risks?

Main risks include conditioning toxicity, low blood counts, infection risk, infertility concerns, hospitalization burden, and the need for long-term follow-up.

Q: When is transplant still preferred?

Transplant may still be preferred when a patient is a strong transplant candidate and the treating team believes donor transplant is the better option.

Gene Therapy for Transfusion-Dependent Beta-Thalassemia

Two FDA-approved gene therapies are available in the U.S. for transfusion-dependent beta-thalassemia: Casgevy for patients 12+ and Zynteglo for adults and children needing regular blood transfusions.

Gene therapy may reduce or eliminate the need for regular transfusions in transfusion-dependent beta-thalassemia, but it requires specialized treatment and long-term follow-up.

Where Gene Therapy Fits in Beta-Thalassemia Care

Gene therapy may be considered for people with transfusion-dependent beta-thalassemia, especially when transfusion burden and iron overload are significant. However, eligibility also depends on overall health, organ function, and the ability to complete intensive treatment and long-term follow-up.

Standard care for many patients includes regular blood transfusions and iron chelation. However, gene therapy may also be considered for patients seeking a longer-term reduction in transfusion needs, especially if they are medically fit for intensive treatment and recovery.

Current FDA-Approved Options

FDA-Approved Option

Casgevy

Approved for patients 12 years and older with transfusion-dependent beta-thalassemia.

Casgevy is a gene-edited autologous hematopoietic stem cell therapy.

Key point: this treatment uses the patient’s own cells after gene editing.

FDA-Approved Option

Zynteglo

Approved for adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Zynteglo is a gene-addition autologous hematopoietic stem cell therapy.

Key point: both products use the patient’s own cells, but the manufacturing approach and product design differ.

Who May Qualify

Eligibility for gene therapy depends on transfusion dependence, organ function, and readiness for intensive treatment and follow-up. Casgevy is approved for patients 12+, while Zynteglo is approved for adults and children needing regular transfusions.

Eligibility

Gene Therapy Eligibility

Point 1

Disease Status

Transfusion-dependent beta-thalassemia or regular red blood cell transfusion requirement.

Point 2

Organ Function

Organ function adequate for intensive therapy.

Point 3

Conditioning Readiness

Readiness for myeloablative conditioning.

Point 4

Follow-Up

Ability to complete prolonged follow-up.

Point 5

Treatment Access

Access to a qualified treatment center.

Point 6

Practical Fitness

Medical and practical fitness for admission and recovery.

Important: eligibility is not based only on the diagnosis. It also depends on whether the patient is medically and practically ready for an intensive treatment process.

Conditioning, Fertility, and Organ Evaluation

Gene therapy for beta-thalassemia involves stem-cell collection, conditioning, infusion of corrected cells, and recovery—not just a single infusion visit. Both Zynteglo and Casgevy use conditioning-based treatment pathways.

Fertility and organ health are important considerations before gene therapy, since conditioning may affect reproductive function and increase risks in patients with complications from chronic transfusions and iron overload. Organ evaluation is therefore a key part of determining whether gene therapy is appropriate.

Expected Benefits and Risks

The main benefit of gene therapy is reducing transfusion burden, and in some cases achieving transfusion independence. In studies, Casgevy showed that 91.4% of treated patients achieved transfusion independence for at least 12 months, while Zynteglo is also approved to help reduce or eliminate regular transfusion needs in eligible patients.

Gene therapy carries significant risks, including conditioning toxicity, low blood counts, infection risk, fertility concerns, and the need for long-term monitoring, which is why treatment is typically managed at experienced centers.

Risks

TIL Therapy Risks

TIL therapy is intensive and can involve meaningful toxicity from chemotherapy, IL-2 support, and the overall hospitalization and recovery process. Not every patient is medically fit enough for this approach, even when the cancer type is relevant.

Chemotherapy toxicity

IL-2 toxicity

Infection risk

Low blood counts

Hospitalization burden

Recovery can take time and may require close monitoring

TIL is not the only path to consider. Depending on the tumor type and treatment history, alternatives may include checkpoint inhibitors, targeted therapy, standard systemic care, other immunotherapy strategies, or clinical trials.

Gene Therapy vs Transplant and Chronic Transfusion Care

Treatment Options

Standard Care vs Gene Therapy

Comparison Point	Gene Therapy	Allogeneic Transplant	Chronic Transfusion Care
Main approach	Uses the patient’s own stem cells with a gene-edited or gene-addition product.	Uses donor stem cells from another person.	Uses regular red blood cell transfusions, often with iron chelation.
Who it may suit	Patients who meet product criteria and can complete an intensive treatment pathway.	Patients with a suitable donor and whose center believes transplant offers a favorable risk-benefit balance.	Patients who are not candidates for gene therapy or transplant, or who prefer a less intensive pathway.
Treatment intensity	Very intensive and includes conditioning, hospital admission, recovery, and prolonged follow-up.	Very intensive and also includes donor-related immune risks.	Less concentrated into one procedure; however, treatment remains ongoing and long term.
Major considerations	Disease burden, organ health, treatment goals, and whether conditioning risks are acceptable.	Donor availability, graft-versus-host disease risk, immune suppression needs, and center experience.	Ongoing transfusion burden, iron overload monitoring, and iron chelation needs.
Helpful patient explanation	One option among several, not the only option.	In some cases, transplant may still be preferred when there is a strong donor option.	Nevertheless, chronic transfusion care remains important for many patients who need disease control without a gene-therapy pathway.

Questions to Ask Your Care Team

Am I eligible for Casgevy, Zynteglo, or both?
Does my level of transfusion dependence make gene therapy reasonable to discuss now?
Is my organ function strong enough for conditioning?
What fertility issues should I discuss before treatment?
How long might the treatment and recovery pathway take?
What are the biggest short-term and long-term risks in my case?
Would transplant still be a better option for me?
What are the alternatives if gene therapy is not the best fit?

FAQ

Is gene therapy available for beta-thalassemia?

Yes. In the U.S., FDA-approved gene therapy is available for transfusion-dependent beta-thalassemia through Casgevy and Zynteglo, with different label wording and age scope.

Does it help patients who need regular transfusions?

Yes, that is the main setting where it is used. Casgevy is approved for transfusion-dependent beta-thalassemia, and Zynteglo is approved for patients with beta-thalassemia who require regular red blood cell transfusions.

What is the difference between Casgevy and Zynteglo?

Casgevy is a gene-editing therapy, while Zynteglo is a gene-addition therapy. Both use the patient’s own stem cells, but they are different products with different manufacturing strategies and label wording.

What are the main risks?

The main risks are the risks of myeloablative conditioning, including severe low blood counts, infection, fertility concerns, and the need for careful hospital-based recovery and long-term follow-up.

treatment and follow-up?

The treatment path includes evaluation, stem-cell collection, manufacturing, conditioning, infusion, marrow recovery, and long-term follow-up. There is not one universal timeline that fits everyone, because recovery and logistics vary by patient and center.

When is transplant still preferred?

Transplant may still be preferred when donor availability, center expertise, disease severity, and the overall risk-benefit balance make it the stronger option. This choice is individualized and should be reviewed at a specialist center.

Clinical Trials:

Medical Disclaimer & Source References
© BEIJING BIOTECH.
Clinical Sources: NCCN, ASCO, ACS, ESMO, CSCO, CACA, ChiCTR.
Regulatory Status: FDA-approved gene therapies are identified where applicable. Other references may be investigational.
Treatment Note: Treatment use, risks, and suitability vary by diagnosis, stage, prior therapy, and patient condition.